A Nanogram Dose of the CYP3A Probe Substrate Midazolam to Evaluate Drug Interactions

Publisher： John Wiley & Sons Inc

E-ISSN： 1532-6535|93|6|564-571

ISSN： 0009-9236

Source： CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol.93, Iss.6, 2013-06, pp. : 564-571

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pharmacokinetic (PK) drug interaction studies of cabozantinib: Effect of CYP3A inducer rifampin and inhibitor ketoconazole on cabozantinib plasma PK and effect of cabozantinib on CYP2C8 probe substrate rosiglitazone plasma PK

By  

JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 55, Iss. 9, 2015-09 ,pp. : 1012-1023

John Wiley & Sons Inc

Access to resources Recommend Favorite

Inhibitory effect of single and repeated doses of nilotinib on the pharmacokinetics of CYP3A substrate midazolam

By  

JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 55, Iss. 4, 2015-04 ,pp. : 401-408

John Wiley & Sons Inc

Access to resources Recommend Favorite

In Vitro Prediction of Clinical Drug Interactions With CYP3A Substrates: We Are Not There Yet

By  

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 95, Iss. 2, 2014-02 ,pp. : 133-135

John Wiley & Sons Inc

Access to resources Recommend Favorite

Evaluation of CYP3A‐mediated drug–drug interactions with romidepsin in patients with advanced cancer

By  

JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 55, Iss. 12, 2015-12 ,pp. : 1378-1385

John Wiley & Sons Inc

Access to resources Recommend Favorite

Evidence of CYP3A Allosterism In Vivo: Analysis of Interaction Between Fluconazole and Midazolam

By  

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 91, Iss. 3, 2012-03 ,pp. : 442-449

John Wiley & Sons Inc

Access to resources Recommend Favorite